To Compare Therapeutic Effect of Intravitreal Bevacizumab and Triamcinolone in Resistant Uveitic Cystoid Macular Edema
试验速览
- 阶段
- 1 期
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Resorbed CME in OCT
研究概览
简要总结
Cystoid macular edema (CME) is one of the common causes of vision loss in patients with UveitiS .Triamcinolone has been effectively used in reducing CME and improving the vision. Also there are some documents which recommend Bevacizumab(avastin) could reduce macular edema. This study compare intravitreous injection of triamcinolone and avastin in patients with resistant uveitic cystoid macular edema.
详细描述
This study compare intravitreous injection of triamcinolone and avastin in patients with resistant uveitic cystoid macular edema.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Uveitic CME
- •Uveitic CME refractory to routine treatment
- •Vision better than 5/200 and worse than 20/50
排除标准
- •Mono- Ocular patients
- •History of vitrectomy
- •Glaucoma or ocular hypertension
- •History of other retinal disease that can cause macular edema
- •Pregnancy
- •Significant media opacity
- •Vision better than 20/50
研究组 & 干预措施
1
Intravitreal injection of Triamcinolone
干预措施: Intravitreal injection of Triamcinolone (Drug)
2
Intravitreal injection of Avastin
干预措施: Intravitreal injection of Avastin (Drug)
结局指标
主要结局
Resorbed CME in OCT
时间窗: every 3 month
Resorbed CME in clinical examination
时间窗: Every 3 month
次要结局
- need to retreatment(when ever needed)